Skip to content
Markets News
Stocks1 min read

Vera Reports Positive Final Results From TRUTAKNA Kidney Trial

Makkler Newsroom
October 22, 2026 · Based on reporting by Business Insider, GlobeNewswire

The ORIGIN 3 analysis met all prespecified endpoints, as Vera plans a supplemental FDA filing later this year.

Key takeaways

  • ORIGIN 3 met its primary endpoint and all prespecified endpoints in the final efficacy analysis.
  • Vera plans to submit a supplemental FDA application in the fourth quarter of 2026.

Vera Therapeutics said its TRUTAKNA treatment met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial in adults with IgA nephropathy. The study had already met its primary endpoint, reducing proteinuria at 36 weeks.

The company reported statistically significant results for kidney-function measures and reduced risk of composite kidney disease progression events. It said the drug’s safety profile was generally comparable to placebo. The indication is currently under accelerated approval based on proteinuria reduction; whether TRUTAKNA slows long-term kidney-function decline has not been established.

Vera plans to submit a supplemental application to the FDA in the fourth quarter of 2026, with full approval expected in 2027, the company said. As of 16:19 UTC on Oct. 22, Vera shares traded at $30.43, down 2.47% from the previous close.

Topics
VERATRUTAKNA

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.